Guggenheim analyst Yatin Suneja raised the firm’s price target on Praxis Precision (PRAX) to $760 from $540 and keeps a Buy rating on the shares after the company presented “compelling” new data from two epilepsy programs at the American Epilepsy Society meeting held this past weekend. The updated RADIANT data for vormatrigine in FOS further de-risk the ongoing POWER 1 study, says the analyst, who adds that Praxis remains one of the firm’s top picks for 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines Shares RADIANT Study Results
- Praxis Precision price target raised to $500 from $360 at Truist
- Praxis Precision price target raised to $353 from $251 at TD Cowen
- Praxis Precision provides clinical updates at AES annual meeting
- Praxis Precision price target raised to $315 from $304 at Needham